GoodRx (NASDAQ:GDRX) Major Shareholder Sells $437,819.12 in Stock

GoodRx Holdings, Inc. (NASDAQ:GDRX) major shareholder Francisco Partners Iv, L.P. sold 127,273 shares of the company’s stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $3.44, for a total transaction of $437,819.12. Following the completion of the sale, the insider directly owned 643,466 shares of the company’s stock, valued at $2,213,523.04. The trade was a 16.51% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Francisco Partners Iv, L.P. also recently made the following trade(s):

• On Wednesday, August 26th, Francisco Partners Iv, L.P. sold 1,296,177 shares of GoodRx stock. The stock was sold at an average price of $3.50, for a total transaction of $4,536,619.50.
• On Monday, August 24th, Francisco Partners Iv, L.P. sold 143,594 shares of GoodRx stock. The stock was sold at an average price of $3.46, for a total value of $496,835.24.
• On Friday, August 21st, Francisco Partners Iv, L.P. sold 274,717 shares of GoodRx stock. The shares were sold at an average price of $3.50, for a total value of $961,509.50.
• On Thursday, August 20th, Francisco Partners Iv, L.P. sold 447,259 shares of GoodRx stock. The shares were sold at an average price of $3.52, for a total value of $1,574,351.68.
• On Wednesday, August 19th, Francisco Partners Iv, L.P. sold 471,975 shares of GoodRx stock. The stock was sold at an average price of $3.53, for a total value of $1,666,071.75.

GoodRx Stock Performance

GDRX stock traded up $0.18 during midday trading on Wednesday, hitting $3.65. The company’s stock had a trading volume of 3,534,816 shares, compared to its average volume of 1,909,305. The stock’s 50-day moving average price is $3.18 and its 200 day moving average price is $2.66. The company has a quick ratio of 1.38, a current ratio of 1.38 and a debt-to-equity ratio of 0.74. GoodRx Holdings, Inc. has a 1 year low of $1.77 and a 1 year high of $5.81. The stock has a market cap of $1.25 billion, a price-to-earnings ratio of 91.27, a PEG ratio of 1.73 and a beta of 1.60.

GoodRx (NASDAQ:GDRX) last announced its quarterly earnings data on Wednesday, August 5th. The company reported $0.08 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.08. GoodRx had a return on equity of 7.22% and a net margin of 2.07%.The firm had revenue of $200.41 million during the quarter, compared to the consensus estimate of $193.23 million. During the same quarter in the prior year, the company earned $0.09 EPS. The business’s revenue for the quarter was down 1.3% on a year-over-year basis. On average, equities analysts forecast that GoodRx Holdings, Inc. will post 0.16 EPS for the current year.

Wall Street Analyst Weigh In

GDRX has been the topic of several research reports. Weiss Ratings raised shares of GoodRx from a “sell (d)” rating to a “sell (d+)” rating in a research report on Friday, August 7th. Wall Street Zen raised shares of GoodRx from a “hold” rating to a “buy” rating in a research report on Saturday, August 15th. TD Cowen raised their price target on shares of GoodRx from $4.00 to $5.00 and gave the stock a “buy” rating in a research note on Tuesday, August 11th. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $4.00 price target on shares of GoodRx in a report on Friday, August 7th. Finally, Leerink Partners set a $5.00 price objective on GoodRx in a research note on Thursday, August 6th. Four equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat, GoodRx presently has a consensus rating of “Hold” and a consensus price target of $4.23.

Hedge Funds Weigh In On GoodRx

Several hedge funds have recently made changes to their positions in the stock. Quarry LP bought a new stake in shares of GoodRx during the 3rd quarter valued at $33,000. Cetera Investment Advisers bought a new stake in shares of GoodRx during the second quarter valued at about $50,000. Boothbay Fund Management LLC purchased a new stake in shares of GoodRx in the third quarter worth about $43,000. Headlands Technologies LLC bought a new position in shares of GoodRx in the second quarter valued at approximately $30,000. Finally, Meridian Wealth Management LLC purchased a new position in GoodRx during the fourth quarter valued at approximately $29,000. 63.77% of the stock is currently owned by hedge funds and other institutional investors.

GoodRx Company Profile

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.